CoChat

Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine

Open access
Singh, Manish Pratap, Rai, Sandhya, Pandey, Ashutosh, Singh, Nand K., Srivastava, Sameer · 2021 · Genes & Diseases
Cited by 146

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical settings. Current treatment strategies in colorectal cancer are largely 'one drug fit all' model for patients that display same pathological conditions. However, CRC is a very heterogenous set of malignancy that does not support for above criteria. Each subtype displays different pathological and genetic signatures. Based on these features, therapeutic stratification for individual patients may be designed, which may ultimately lead to improved therapeutic outcomes. In this comprehensive review, we have attempted to briefly outline major CRC pathways. A detailed overview of molecular subtypes and their clinical significance has been discussed. Present and future methods, governing CRC subtyping in the era of personalized therapy with a special emphasis on CMS subtypes of CRC has been reviewed. Together, discovery and validation of new CRC patient stratification methods, screening for novel therapeutic targets, and enhanced diagnosis of CRC may improve the treatment outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.gendis.2019.10.013

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 79

  1. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J Clin, 68, 394
  2. Nakayama, 2013, Current options for the diagnosis, staging and therapeutic management of colorectal cancer, Gastrointest Tumours, 1, 25, 10.1159/000354995 · DOI
  3. Mundade, 2014, Genetic pathways, prevention, and treatment of sporadic colorectal cancer, Oncoscience, 1, 400, 10.18632/oncoscience.59 · DOI
  4. Worthley, 2007, Colorectal carcinogenesis: road maps to cancer, World J Gastroenterol, 13, e3784, 10.3748/wjg.v13.i28.3784 · DOI
  5. Pino, 2010, The chromosomal instability pathway IN colon cancer, Gastroenterology, 138, 2059, 10.1053/j.gastro.2009.12.065 · DOI · Paper page
  6. Esteller, 2001, A gene hypermethylation profile of human cancer, Cancer Res, 61, 3225
  7. Hewish, 2010, Mismatch repair deficient colorectal cancer in the era of personalized treatment, Nat Rev Clin Oncol, 7, 197, 10.1038/nrclinonc.2010.18 · DOI · Paper page
  8. Migliore, 2011, Genetics, cytogenetics, and epigenetics of colorectal cancer, J Biomed Biotechnol, 2011, e792362
  9. Weisenberger, 2015, Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history, Cancer Epidemiol Biomark Prev, 24, 512, 10.1158/1055-9965.EPI-14-1161 · DOI
  10. Curtin, 2011, CpG island methylation in colorectal cancer: past, present and future, Pathol Res Int, 2011, 10.4061/2011/902674 · DOI · Paper page
  11. Ogino, 2007, Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample, J Mol Diagn, 9, 305, 10.2353/jmoldx.2007.060170 · DOI · Paper page
  12. Toyota, 2000, Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype, Proc Natl Acad Sci USA, 97, 710, 10.1073/pnas.97.2.710 · DOI · Paper page
  13. Weisenberger, 2006, CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, Nat Genet, 38, 787, 10.1038/ng1834 · DOI · Paper page
  14. Toyota, 1999, CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci U S A, 96, 8681, 10.1073/pnas.96.15.8681 · DOI · Paper page
  15. Shen, 2007, Methods of DNA methylation analysis, Curr Opin Clin Nutr Metab Care, 10, 576
  16. Yagi, 2010, Three DNA methylation epigenotypes in human colorectal cancer, Clin Cancer Res, 16, 21, 10.1158/1078-0432.CCR-09-2006 · DOI · Paper page
  17. Sjöblom, 2006, The consensus coding sequences of human breast and colorectal cancers, Science, 314, 268, 10.1126/science.1133427 · DOI · Paper page
  18. Leary, 2008, Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers, Proc Natl Acad Sci USA, 105, 16224, 10.1073/pnas.0808041105 · DOI · Paper page
  19. Jass, 2007, Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, Histopathology, 50, 113, 10.1111/j.1365-2559.2006.02549.x · DOI · Paper page
  20. Lee, 2008, Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation, Pathol Int, 58, 104, 10.1111/j.1440-1827.2007.02197.x · DOI · Paper page
  21. Nosho, 2008, PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations, Neoplasia, 10, 534, 10.1593/neo.08336 · DOI · Paper page
  22. Ward, 2003, Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability, J Clin Oncol, 21, 3729, 10.1200/JCO.2003.03.123 · DOI · Paper page
  23. Ogino, 2008, Molecular classification and correlates in colorectal cancer, J Mol Diagn, 10, 13, 10.2353/jmoldx.2008.070082 · DOI · Paper page
  24. Saltz, 2004, Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803), J Clin Orthod, 22, e3500
  25. Shiovitz, 2014, CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage 3 colon cancer, Gastroenterology, 147, 637, 10.1053/j.gastro.2014.05.009 · DOI · Paper page
  26. Han, 2013, Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer, Int J Cancer, 132, 2209, 10.1002/ijc.27888 · DOI
  27. Sinicrope, 2016, Molecular biomarkers in the personalized treatment of colorectal cancer, Clin Gastroenterol Hepatol, 14, 651, 10.1016/j.cgh.2016.02.008 · DOI · Paper page
  28. Ogino, 2006, CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations, J Mol Diagn, 8, 582, 10.2353/jmoldx.2006.060082 · DOI · Paper page
  29. Ogino, 2007, Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype, Hum Pathol, 38, 842, 10.1016/j.humpath.2006.11.018 · DOI
  30. Goel, 2007, The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer, Gastroenterology, 132, 127, 10.1053/j.gastro.2006.09.018 · DOI · Paper page
  31. Samowitz, 2005, Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer, Gastroenterology, 129, 837, 10.1053/j.gastro.2005.06.020 · DOI · Paper page
  32. Ogino, 2007, Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer, Gut, 56, 1564, 10.1136/gut.2007.119750 · DOI
  33. Ogino, 2007, 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high, BMC Canc, 7, e72, 10.1186/1471-2407-7-72 · DOI
  34. Van der Flier, 2007, The intestinal Wnt/TCF signature, Gastroenterology, 132, 628, 10.1053/j.gastro.2006.08.039 · DOI · Paper page
  35. Khambata-Ford, 2007, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, 25, 3230, 10.1200/JCO.2006.10.5437 · DOI · Paper page
  36. Sadanandam, 2013, A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nat Med, 19, 619, 10.1038/nm.3175 · DOI · Paper page
  37. Jorissen, 2008, DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers, Clin Cancer Res, 14, 8061, 10.1158/1078-0432.CCR-08-1431 · DOI · Paper page
  38. Jorissen, 2009, Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer, Clin Cancer Res, 15, 7642, 10.1158/1078-0432.CCR-09-1431 · DOI · Paper page
  39. Roepman, 2014, Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition, Int J Cancer, 134, 552, 10.1002/ijc.28387 · DOI · Paper page
  40. Cancer Genome Atlas Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
  41. Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
  42. Sinicrope, 2013, Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy, J Clin Oncol, 31, 3664, 10.1200/JCO.2013.48.9591 · DOI · Paper page
  43. Ogino, 2009, CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer, Gut, 58, 90, 10.1136/gut.2008.155473 · DOI · Paper page
  44. Deschoolmeester, 2011, Immune cells in colorectal cancer: prognostic relevance and role of MSI, Canc Microenviron, 4, 377, 10.1007/s12307-011-0068-5 · DOI
  45. De Smedt, 2015, Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis, Br J Canc, 113, 500, 10.1038/bjc.2015.213 · DOI
  46. Park, 2016, Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment, Br J Canc, 114, 562, 10.1038/bjc.2016.17 · DOI
  47. Singh, 2015, Immune checkpoints and immunotherapy for colorectal cancer, Gastroenterol Rep (Oxf), 3, 289
  48. Teng, 2015, IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases, Nat Med, 21, 719, 10.1038/nm.3895 · DOI · Paper page
  49. Najdi, 2011, Wnt signaling and colon carcinogenesis: beyond APC, J Carcinog, 10, e5, 10.4103/1477-3163.78111 · DOI · Paper page
  50. Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br J Canc, 108, 1757, 10.1038/bjc.2013.118 · DOI · Paper page
  51. Ghidini, 2016, KRAS mutation in lung metastases from colorectal cancer: prognostic implications, Cancer Med, 5, 256, 10.1002/cam4.592 · DOI
  52. Hagland, 2013, Molecular pathways and cellular metabolism in colorectal cancer, Dig Surg, 30, 12, 10.1159/000347166 · DOI
  53. Fang, 2016, Advances in glucose metabolism research in colorectal cancer, Biomed Rep, 5, 289, 10.3892/br.2016.719 · DOI
  54. Chen, 2015, Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism, OncoTarget, 6, 24148, 10.18632/oncotarget.4376 · DOI
  55. Chen, 2018, Propofol elicits autophagy via endoplasmic reticulum stress and calcium exchange in C2C12 myoblast cell line, PLoS One, 13, e0197934, 10.1371/journal.pone.0197934 · DOI
  56. Satoh, 2017, Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC, Proc Natl Acad Sci, 114, E7697, 10.1073/pnas.1710366114 · DOI · Paper page
  57. Park, 2014, The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer, Ann Oncol, 25, 644, 10.1093/annonc/mdt593 · DOI · Paper page
  58. Staudacher, 2017, Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer, Sci Rep, 7, e5569, 10.1038/s41598-017-05907-8 · DOI · Paper page
  59. de Gramont, 2016, Novel TGF-β inhibitors ready for prime time in onco-immunology, OncoImmunology, 6, e1257453, 10.1080/2162402X.2016.1257453 · DOI · Paper page
  60. Sadanandam, 2014, Reconciliation of classification systems defining molecular subtypes of colorectal cancer, Cell Cycle, 13, 353, 10.4161/cc.27769 · DOI · Paper page
  61. Garza-Treviño, 2015, Understanding the colon cancer stem cells and perspectives on treatment, Cancer Cell Int, 15, e2, 10.1186/s12935-015-0163-7 · DOI
  62. Pogue-Geile, 2016, Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: results from NRG Oncology/NSABP C-07, J Clin Orthod, 34, e3510
  63. Qiu, 2018, Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer, OncoTargets Ther, 11, 465, 10.2147/OTT.S149110 · DOI
  64. Graham, 2016, Molecular subtypes and personalized therapy in metastatic colorectal cancer, Curr Colorectal Canc Rep, 12, 141
  65. Rodriguez-Salas, 2017, Clinical relevance of colorectal cancer molecular subtypes, Crit Rev Oncol Hematol, 109, 9, 10.1016/j.critrevonc.2016.11.007 · DOI
  66. Dorard, 2011, Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis, Nat Med, 17, 1283, 10.1038/nm.2457 · DOI · Paper page
  67. Koenig, 2018, Microsatellite instability and adjuvant chemotherapy in stage II colon cancer, J Clin Orthod, 36, e767
  68. Douillard, 2014, First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study, Br J Canc, 110, 55, 10.1038/bjc.2013.721 · DOI · Paper page
  69. Ciardiello, 2016, Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX, Ann Oncol, 27, 1055, 10.1093/annonc/mdw136 · DOI
  70. Peeters, 2015, Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer, Clin Cancer Res, 21, 5469, 10.1158/1078-0432.CCR-15-0526 · DOI · Paper page
  71. Rowland, 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer, Br J Canc, 112, 1888, 10.1038/bjc.2015.173 · DOI · Paper page
  72. Kopetz, 2017, Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406), J Clin Orthod, 35, e520
  73. Overman, 2016, Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results, J Clin Orthod, 34, e3501
  74. Lemery, 2017, First FDA approval agnostic of cancer site - when a biomarker defines the indication, N Engl J Med, 377, 1409, 10.1056/NEJMp1709968 · DOI · Paper page
  75. Siravegna, 2017, Integrating liquid biopsies into the management of cancer, Nat Rev Clin Oncol, 14, 531, 10.1038/nrclinonc.2017.14 · DOI · Paper page
  76. Ogino, 2018, Immunoscore for (colorectal) cancer precision medicine, The Lancet, 391, 2084, 10.1016/S0140-6736(18)30953-X · DOI
  77. Martin, 2013, HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients, Br J Canc, 108, 668, 10.1038/bjc.2013.4 · DOI · Paper page
  78. Laurent-Puig, 2016, ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8), Ann Oncol, 27, vi149
  79. Madan, 2016, Wnt addiction of genetically defined cancers reversed by PORCN inhibition, Oncogene, 35, 2197, 10.1038/onc.2015.280 · DOI · Paper page

Cited by

See all 146

Metadata

Authors
Singh, M. P., Rai, S., Pandey, A., Singh, N. K., & Srivastava, S.
Venue
Genes & Diseases
Publisher
Elsevier BV
Published
2021-03
Volume
8
Issue
2
Pages
133-145
ISSN
2352-3042 (ISSN-L)
OpenAlex
W2985795188
Cited by
146
References
23
FWCI
3.36
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Department of Biotechnology, Government of West Bengal
  • Department of Biotechnology, Ministry of Science and Technology, India (6242-P103/RGCB/PMD/DBT/SMSV/2015)
  • Council of Scientific and Industrial Research, India
  • Ministry of Education, India

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine. https://app.cochat.ai/papers/10.1016/j.gendis.2019.10.013
The paper
Singh, M. P., Rai, S., Pandey, A., Singh, N. K., & Srivastava, S. (2021). Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine. Genes & Diseases. https://doi.org/10.1016/j.gendis.2019.10.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.